Palvella Therapeutics, a clinical-stage biopharmaceutical company, has released the topline results from its Phase 3 VAPAUS study of QTORIN™ rapamycin gel for the treatment of Pachyonychia Congenita (PC). The study did not show a treatment effect on the primary endpoint. However, it is important to note that the drug was well-tolerated with no serious adverse events reported. As a result, Palvella does not plan to invest in further studies or commercial preparation activities for QTORIN rapamycin. The company intends to share these findings with key stakeholders.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare genetic skin diseases without FDA-approved treatments, has announced the topline results from their pivotal Phase 3 study called VAPAUS. This 24-week study involved randomized, double-blind, placebo-controlled trials of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) as a potential